Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | SAKK 11/16: MVX-ONCO-1, a novel vaccine, in pre-treated RMHNSCC

Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland, discusses findings from the Phase IIa SAKK 11/16 trial (NCT02999646) of MVX-ONCO-1, a vaccine for patients with pre-treated recurrent/metastatic head & neck squamous cell carcinoma (RMHNSCC). Patients have typically progressed on pembrolizumab or nivolumab and the vaccine resulted in prolonged survival, where a few cases of complete response reported. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.